Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2012 1
2013 1
2015 2
2016 4
2017 4
2018 3
2019 5
2020 4
2021 5
2022 5
2023 7
2024 10
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators. Ahn MJ, et al. J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9. J Clin Oncol. 2025. PMID: 39250535 Free PMC article. Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Mechanisms of resistance to antibody-drug conjugates in cancers.
Murase Y, Nanjo S, Ueda T, Liu Y, Nomura S, Arai S, Terada N, Koba H, Tambo Y, Yano S. Murase Y, et al. Among authors: tambo y. Respir Investig. 2025 Jul;63(4):693-698. doi: 10.1016/j.resinv.2025.05.012. Epub 2025 Jun 2. Respir Investig. 2025. PMID: 40460510 Review.
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M. Tanaka H, et al. Among authors: tambo y. Eur J Cancer. 2024 Dec;213:115117. doi: 10.1016/j.ejca.2024.115117. Epub 2024 Nov 5. Eur J Cancer. 2024. PMID: 39522333 Free article.
Unexpected Diffuse Alveolar Hemorrhage After Bronchoscopy.
Tsukida S, Watanabe S, Hongo M, Murase Y, Yamamoto Y, Kase K, Terada N, Koba H, Tambo Y, Yano S. Tsukida S, et al. Among authors: tambo y. Chest. 2023 Sep;164(3):e71-e74. doi: 10.1016/j.chest.2023.04.027. Chest. 2023. PMID: 37689476
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study.
Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S. Tambo Y, et al. Lung Cancer. 2025 Mar;201:108422. doi: 10.1016/j.lungcan.2025.108422. Epub 2025 Feb 4. Lung Cancer. 2025. PMID: 39952082 Free article.
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y, Nomura S, Sakakibara-Konishi J, Tsukita Y, Murakami S, Hosomi Y, Tambo Y, Kogure Y, Yoshioka H, Tamiya M, Ninomiya K, Iwama E. Okuma Y, et al. Among authors: tambo y. Clin Lung Cancer. 2024 Jun;25(4):389-394. doi: 10.1016/j.cllc.2024.02.002. Epub 2024 Feb 8. Clin Lung Cancer. 2024. PMID: 38413246 Clinical Trial.
48 results